PRESS RELEASE published on 03/27/2026 at 07:30, 3 months 22 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 3 months 26 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 4 months ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
PRESS RELEASE published on 03/18/2026 at 10:15, 4 months ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 4 months 8 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 4 months 8 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 4 months 9 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 4 months 9 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 4 months 9 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 5 months ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
Published on 07/17/2026 at 15:00, 21 hours 13 minutes ago Four Nines Gold to Showcase Hayden Hill Opportunity to U.S. Investors at OTC Markets Virtual Investor Conference
Published on 07/17/2026 at 14:00, 22 hours 13 minutes ago Redwood AI Announces Pricing of $3.5 Million Private Placement
Published on 07/17/2026 at 13:00, 23 hours 13 minutes ago Blue Lagoon Surpasses $10 Million In Revenue As Dome Mountain Production Rises To 125 Tonnes Per Day
Published on 07/17/2026 at 01:00, 1 day 11 hours ago RJK Explorations Ltd. Announces Closing of Private Placement for Gross Proceeds of $310,000
Published on 07/17/2026 at 00:00, 1 day 12 hours ago LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline
Published on 07/18/2026 at 08:00, 4 hours 13 minutes ago Northern Data AG – Changes to the Supervisory Board and the Management Board
Published on 07/17/2026 at 20:35, 15 hours 38 minutes ago Farizon Opens Global Spare Part Distribution Center to Strengthen International Aftersales Support
Published on 07/17/2026 at 18:55, 17 hours 18 minutes ago CGTN: China vows to make AI a driver for shared prosperity amid widening AI divide
Published on 07/17/2026 at 18:32, 17 hours 41 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/17/2026 at 18:31, 17 hours 42 minutes ago Disclosure of transactions in own shares from July 13 to July 17, 2026
Published on 07/17/2026 at 18:00, 18 hours 13 minutes ago Information regarding compliance with gender balance rules within the Board of Directors
Published on 07/17/2026 at 17:45, 18 hours 28 minutes ago Imerys-07-2026-information-share-capital-and-voting-rights-as-of-30-June-2026
Published on 07/16/2026 at 18:08, 1 day 18 hours ago Aéroports de Paris S.A - June and half-year 2026 traffic figures
